付琴，華中科技大學同濟醫學院88858cc永利官网藥理學系教授，博士生導師。德國柏林Max-Delbrueck分子醫學中心訪問學者；美國伊利諾伊大學香槟分校和加州大學戴維斯分校博士後。現任中國藥理學會心血管藥理學專業委員會常務委員，表觀遺傳藥理專業委員會委員，湖北省藥理學會副理事長。擔任Diabetes，British Journal of Pharmacology，Pharmacological Research，FASEB Journal等期刊特約審稿人。主持多項國家自然科學基金面上項目以及海外合作項目；研究成果發表在Circulation、Diabetes、JMCC、BJP、JBC等期刊，并獲得湖北省科技進步一等獎（2019）。

主要研究方向：

1. 心血管疾病和代謝綜合征的發病機制和藥物幹預靶點

2. 腎上腺素受體/磷酸二酯酶信号通路調控心髒和肝髒疾病的作用機制

聯系方式：fuqin@tjmu.edu.cn

承擔課題：

1.國家自然科學基金，β2腎上腺素受體調控CD36介導的心肌細胞和心髒成纖維細胞代謝重塑在心梗後心衰中的雙向作用及機制研究

2.國家自然科學基金，PDE4調控的心髒成纖維細胞miR-1應答高胰島素血症在糖尿病心肌纖維化中的作用機制及幹預研究，

3.國家自然科學基金海外及港澳學者合作研究基金延續項目，β2腎上腺素受體依賴性的胰島素促心肌GLUT4轉運對β受體阻滞劑抗糖尿病心力衰竭療效的影響

4.國家自然科學基金，β2腎上腺素受體依賴性的胰島素誘導的PDE4在糖尿病心功能不全中的作用

5.國家自然科學基金海外及港澳學者合作研究基金，神經激素對β腎上腺素受體阻斷劑抗心力衰竭療效的影響，

6.國家自然科學基金，ERK1/2-CX43信号通路在β2腎上腺素受體激動劑抗心肌缺血再灌注損傷中的作用

發表學術論文（#Co-first author , *Co-corresponding author)：

1. Fu Q,Wang Y, Yan C, Xiang YK. Phosphodiesterases in heart and vessels- From Physiology to Diseases. Physiol Rev.2024 Apr 1;104(2):765-834.

2. Fu J^#, Li L^#, Chen L, Su C, Feng X, Huang K, Zhang L*, Yang X*,Fu Q*. PGE2 protects against heart failure through inhibiting TGF-β1 synthesis in cardiomyocytes and crosstalk between TGF-β1 and GRK2. J Mol Cell Cardiol. 2022 Nov; 172:63-77.

3. Xu R^#, Fu J^#, Hu Y, Yang X, Tao X, Chen L, Huang K,Fu Q. Roflumilast-Mediated Phosphodiesterase 4D Inhibition Reverses Diabetes-Associated Cardiac Dysfunction and Remodeling: Effects Beyond Glucose Lowering.Diabetes. 2022 2022 Aug 1;71(8):1660-1678.

4. Ren H, Chen Y, Ao Z, Cheng Q, Yang X, Tao H, Zhao L, Shen A, Li P*,Fu Q*.PDE4D binds and interacts with YAP to cooperatively promote HCC progression.Cancer Lett. 2022 Aug 10;541:215749

5. Xu R, Feng S, Chen Y, Ao Z, Su C, Feng X,Fu Q*, Yang X*.Long-Acting β2 Adrenergic Receptor Agonist Ameliorates Imiquimod-Induced Psoriasis-Like Skin Lesion by Regulating Keratinocyte Proliferation and Apoptosis.Front. Pharmacol. 2022 Jun 20:13:865715

6. Tao X, Chen C, Chen Y, Zhang L, Hu J, Yu H, Liang M,Fu Q*, Huang K*. β2-adrenergic receptor promotes liver regeneration partially through crosstalk with c-met.Cell Death Dis. 2022 Jun 27;13(6):571

7. Tao X, He H, Peng J, Xu R, Fu J, Hu Y, Li L, Yang X, Feng X, Zhang C, Zhang L, Yu X, Shen A*, Huang K*,Fu Q*. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast.Pharmacol Res. 2022 Jan;175:106004.

8. Xu R^#, Gopireddy RR^#, Wu Y^#, Wu L, Tao X, Shao J, Wang W, Li L, Jovanovic A, Xu B, Kenyon NJ, Lu Q, Xiang YK*,Fu Q*. Hyperinsulinemia promotes heterologous desensitization of β2 adrenergic receptor in airway smooth muscle in obesity.FASEB J. 2020 Mar;34(3):3996-4008.

9. Fu Q^*, Wang Q^*, Xiang YK^*Insulin and β Adrenergic Receptor Signaling: Crosstalk in Heart.Trends Endocrinol Metab. 2017 Jun;28(6):416-427 .

10. Wang Q^#, Liu Y^#,Fu Q^#, Xu B, Zhang Y, Kim S, Tan R, Barbagallo F, West T, Anderson E, Wei W, Abel ED, Xiang YK. Inhibiting Insulin-Mediated β2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction.Circulation. 2017 Jan 3;135(1):73-88.

11. Fu Q^#*,Kim S^#, Soto D, De Arcangelis V, Dipilato L, Liu S, Xu B, Zhang J, Shi Q, Xiang YK*. A long-lasting β1 adrenergic receptor stimulation of cAMP/PKA signals in cardiac myocytes. J Biol Chem.2014 May 23;289(21):14771-81

12. Fu Q, Xu B, Liu Y, Parikh D, Li J, Li Y, Zhang Y, Riehle C, Zhu Y, Rawlings T, Shi Q, Clark RB, Chen X, Abel ED, Xiang YK. Insulin inhibits cardiac contractility by inducing a Gi-biased β2 adrenergic signaling in hearts.Diabetes.2014 Aug;63(8):2676-89

13. Fu Q^*, Hu Y, Wang Q, Liu Y, Li N, Xu B, Kim S, Chiamvimonvat N, Xiang YK^*. High-fat diet induces protein kinase A and G-protein receptor kinase phosphorylation of β(2) -adrenergic receptor and impairs cardiac adrenergic reserve in animal hearts.J Physiol. 2017 Mar 15;595(6):1973-1986.